In the clinic this suggests that more powerful innate agonists can deliver greater therapeutic benefit and that the advent of anti-human CTLA-4 antibodies with the capacity to deplete Tregs, particularly in a tumor-selective fashion, could profoundly improve outcomes against poorly immunogenic cancers. This evidence concerns the gene CTLA4 and neoplasm.